News | September 28, 2023
Sun Pharma Canada launches Prwinlevi for treatment for acne
WINLEVI works differently from any other topical acne treatment
WINLEVI works differently from any other topical acne treatment
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
